Abstract
Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Current Enzyme Inhibition
Title:Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Volume: 12 Issue: 2
Author(s): Bijo Mathew, Githa E. Mathew, Jerad Suresh, Gülberk Ucar, Rani Sasidharan, Sockalingam Anbazhagan, Jobin K. Vilapurathu and Venkatesan Jayaprakash
Affiliation:
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Abstract: Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Export Options
About this article
Cite this article as:
Mathew Bijo, Mathew E. Githa, Suresh Jerad, Ucar Gülberk, Sasidharan Rani, Anbazhagan Sockalingam, Vilapurathu K. Jobin and Jayaprakash Venkatesan, Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders, Current Enzyme Inhibition 2016; 12 (2) . https://dx.doi.org/10.2174/1573408012666160402001715
DOI https://dx.doi.org/10.2174/1573408012666160402001715 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Neuroprotection of Thioredoxin1 in the Brain
Current Alzheimer Research An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Current Medicinal Chemistry Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Dosage and Passage Dependent Neuroprotective Effects of Exosomes Derived from Rat Bone Marrow Mesenchymal Stem Cells: An In Vitro Analysis
Current Gene Therapy The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Genetic and Environmental Modifiers of Alzheimers Disease Phenotypes in the Mouse
Current Alzheimer Research Bibliometrics and Visualization of the Mechanisms of Parkinson's Diseases Based on Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs
Current Immunology Reviews (Discontinued) Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry Is PrP(106-126) Fragment Involved in the Membrane Activity of the Prion Protein?
Current Protein & Peptide Science Patent Selections
Recent Patents on Biotechnology Antioxidant and Acetylcholinesterase Inhibitory Potential of Thai Medicinal Plants
Current Nutrition & Food Science Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets From the Editors Perspective: Inflammatory Glial Cells of the Nervous System: Assistants or Assassins?
Current Neurovascular Research